Ken Fisher Fisher Asset Management
Ken Fisher is the founder and executive chairman of Fisher Investments, a global money management firm overseeing billions of dollars in assets. He gained early recognition for pioneering the use of the price-to-sales ratio in stock analysis and wrote the long-running “Portfolio Strategy” column in Forbes. Over the years, Fisher has authored numerous books on investing and wealth management, many of which have become bestsellers.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
FLGE
Credit Suisse FI Large Cap Growth Enhanced Exchange Traded Notes
FLGE
|
+$499M |
| 2 |
FBGX
UBS AG FI Enhanced Large Cap Growth ETN
FBGX
|
+$479M |
| 3 |
Merck
MRK
|
+$328M |
| 4 |
BAY
BAYER AG SPONS ADR
BAY
|
+$287M |
| 5 |
Lloyds Banking Group
LYG
|
+$275M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
FBG
UBS AG LONDON BRH FISHER ENHANCED BIG CAP GROWTH ETN
FBG
|
+$958M |
| 2 |
IBM
IBM
|
+$565M |
| 3 |
McDonald's
MCD
|
+$502M |
| 4 |
CSE
CAPITALSOURCE INC
CSE
|
+$95.8M |
| 5 |
PL
PROTECTIVE LIFE CORP
PL
|
+$66.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 19.81% |
| 2 | Healthcare | 13.89% |
| 3 | Technology | 12.13% |
| 4 | Industrials | 7.64% |
| 5 | Consumer Discretionary | 5.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
176
Integra LifeSciences
IART
$1.33B
| $25M | 0.05% |
1,302,074
-102,727
| -7% | -$1.91M |
|
177
eBay
EBAY
$50.4B
| $24.9M | 0.05% |
1,182,730
+501,533
| +74% | +$10.9M |
|
178
Extra Space Storage
EXR
$31.3B
| $24.2M | 0.05% |
454,767
-12,745
| -3% | -$657K |
|
179
Gerdau
GGB
$9.74B
| $23.5M | 0.05% |
5,028,592
+841,157
| +20% | +$4.12M |
|
180
Vanguard FTSE Europe ETF
VGK
$30.8B
| $23.5M | 0.05% |
391,782
+25,169
| +7% | +$1.52M |
|
|
VRE
181
DELISTED
Veris Residential
VRE
| $23.4M | 0.05% |
1,089,360
-4,675
| -0.4% | -$98.8K |
|
|
SGI
182
Somnigroup International
SGI
$14.1B
| $23.1M | 0.05% |
1,549,740
-94,200
| -6% | -$1.26M |
|
|
SNDK
183
DELISTED
SANDISK CORP
SNDK
| $23M | 0.05% |
220,011
+14,009
| +7% | +$1.27M |
|
|
AZPN
184
DELISTED
ASPEN TECHNOLOGY INC
AZPN
| $22.8M | 0.05% |
490,414
+272,170
| +125% | +$12.6M |
|
|
CNL
185
DELISTED
CLECO CRP (HOLDING CO)
CNL
| $22.6M | 0.05% |
383,760
-975
| -0.3% | -$50.8K |
|
186
MKS Inc
MKSI
$19.8B
| $22.6M | 0.05% |
722,524
-37,225
| -5% | -$1.08M |
|
|
CBD
187
DELISTED
Companhia Brasileira de Distribuicao
CBD
| $22.4M | 0.05% |
482,679
+248,994
| +107% | +$11.7M |
|
188
State Street Financial Select Sector SPDR ETF
XLF
$56.8B
| $21.9M | 0.05% |
1,098,464
+76,299
| +7% | +$1.49M |
|
|
FRC
189
DELISTED
First Republic Bank
FRC
| $21.8M | 0.05% |
397,148
+91,018
| +30% | +$4.78M |
|
|
SAPE
190
DELISTED
SAPIENT CORP
SAPE
| $21.6M | 0.05% |
1,332,351
+186,281
| +16% | +$3.06M |
|
191
Union Pacific
UNP
$172B
| $21.5M | 0.05% |
215,225
+90,875
| +73% | +$8.81M |
|
192
Ameriprise Financial
AMP
$48.1B
| $20.7M | 0.04% |
172,382
+9,465
| +6% | +$1.06M |
|
193
COPT Defense Properties
CDP
$4.35B
| $20M | 0.04% |
718,138
-650
| -0.1% | -$17.8K |
|
194
Charles River Laboratories
CRL
$11.3B
| $19.9M | 0.04% |
371,824
+161,112
| +76% | +$8.84M |
|
195
AAR Corp
AIR
$5.56B
| $19.2M | 0.04% |
+697,620
| New | +$18.1M |
|
|
196
IBM
IBM
$209B
| $18.7M | 0.04% |
107,801
-3,137,719
| -97% | -$565M |
|
|
STJ
197
DELISTED
St Jude Medical
STJ
| $18M | 0.04% |
260,414
+3,144
| +1% | +$204K |
|
198
Cullen/Frost Bankers
CFR
$10.3B
| $17.8M | 0.04% |
224,414
+33,084
| +17% | +$2.55M |
|
199
Zimmer Biomet
ZBH
$18.4B
| $17.7M | 0.04% |
175,163
-1,554
| -0.9% | -$152K |
|
200
Invesco QQQ Trust
QQQ
$450B
| $17.6M | 0.04% |
186,905
-14,628
| -7% | -$1.31M |
|
Similar funds
Ken Fisher's Q2 2014 Portfolio in Review
As of Q2 2014, Ken Fisher held 668 positions worth $47.6B, up 7.3% from $44.3B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Ken Fisher deployed $2.03B of net new capital in Q2 2014, opening 82 new positions and adding to 273 existing holdings. Its largest new stake was Credit Suisse FI Large Cap Growth Enhanced Exchange Traded Notes: 5,003,089 shares worth $506M.
By sector, the portfolio is most concentrated in Financials at 20% of assets, down from 20% a quarter earlier, followed by Healthcare and Technology.
On the sell side, the largest reduction was UBS AG LONDON BRH FISHER ENHANCED BIG CAP GROWTH ETN, an estimated $958M trimmed.
- Ken Fisher's largest Q2 2014 buy was Credit Suisse FI Large Cap Growth Enhanced Exchange Traded Notes: 5,003,089 shares worth $506M.
- Ken Fisher added most to Merck in Q2 2014, an estimated $328M increase.
- Ken Fisher's biggest Q2 2014 reduction was UBS AG LONDON BRH FISHER ENHANCED BIG CAP GROWTH ETN, cutting an estimated $958M.
- Ken Fisher fully exited CAPITALSOURCE INC in Q2 2014, selling an estimated $95.8M.
- Ken Fisher's ten largest holdings make up 23% of its $47.6B portfolio in Q2 2014.
- Ken Fisher opened 82 new positions and closed 70 in Q2 2014.
- Ken Fisher's portfolio value rose 7.3% quarter-over-quarter to $47.6B.
Based on Fisher Asset Management's 13F filing for Q2 2014, filed 25 Jul 2014.